Luminex has appointed Harriss Currie vice president of finance and chief financial officer. Currie, 41, served as acting CFO and controller since March 2002, when CFO Frank Reeves left the company after less than one year on the job.
Cylex has hired for Visible Genetics COO Timothy Ellis as president. Cylex said his appointment will “enhance” the company’s chances of entering “into a new era of individualized therapy and predictive medicine,” Cylex said this week.
Mark Perry has been appointed to the board of directors of Nuvelo, the Sunnyvale, Calif., firm that resulted from the merger of Hyseq and Variagenics, the company said Oct. 14.
Perry, the executive vice president of operations at Gilead Sciences, replaces Jean-Francois Formela, a principal at Atlas Ventures, who resigned from the Nuvelo board on Oct. 13.
Perry has been at Gilead since 1994, and has served as vice president, general counsel and secretary, as well as CFO, before assuming his current duties in 2000. Prior to joining Gilead, Perry was a partner at the San Francisco office of the law firm Cooley Godward. He is also currently on the board of DNA Sciences and IntraBiotics Pharmaceuticals.
Marvin Selter and Richard Wennenkamp have been appointed to the board of CytRx, a Los Angeles-based firm that focuses on RNAi-based therapeutics, the company said Oct. 10.
Selter and Wennenkamp replace Raymond Carnahan and Herbert McDade, who retired Oct. 10.
Selter is president of CMS, a management consulting firm, and serves on the boards of UCLA Medical Center, the San Fernando Economic Alliance, the Valley Economic Development Center and the California State University-Northridge Economic Development Center.
Wennenkamp is senior vice president of credit administration at Community Bank in Pasadena, Calif. Previously, he was managing director of credit product at Bank of America. He also was also executive director of the Ford Transition office, and was a staff assistant to the President, CytRx sid in a statement this week.